Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer

The aim of this study was to assess the cost-effectiveness of combination chemotherapy with paclitaxel/cisplatin, compared with standard etoposide/cisplatin in patients with advanced non-small cell lung cancer (NSCLC). We obtained the primary survival and resource utilization data from a large three...

Descripción completa

Detalles Bibliográficos
Autores principales: Earle, C C, Evans, W K
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362269/
https://www.ncbi.nlm.nih.gov/pubmed/10360660
http://dx.doi.org/10.1038/sj.bjc.6690426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362269/
https://www.ncbi.nlm.nih.gov/pubmed/10360660
http://dx.doi.org/10.1038/sj.bjc.6690426

Ejemplares similares